Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA: 688192)

China flag China · Delayed Price · Currency is CNY
47.43
+0.55 (1.17%)
Nov 11, 2024, 2:56 PM CST
4.70%
Market Cap 19.19B
Revenue (ttm) 389.64M
Net Income (ttm) -837.22M
Shares Out 415.65M
EPS (ttm) -2.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,489,321
Open 47.62
Previous Close 46.88
Day's Range 46.90 - 48.97
52-Week Range 24.82 - 54.58
Beta 0.27
Analysts n/a
Price Target n/a
Earnings Date Oct 29, 2024

About Dizal (Jiangsu) Pharmaceutical

Dizal (Jiangsu) Pharmaceutical Co., Ltd. discovers, develops, and commercializes medicines in the areas of cancer and immunological diseases. It develops JAUKPO, which is in Phase II clinical trials for the treatment of hematological malignancy and immunological diseases; DZD8586 that is in Phase I for the treatment of hematological malignancy; ZEGFROVY, which is in Phase II clinical trials for the treatment of solid tumors; DZD1516 that is in Phase II clinical trials for the treatment of solid tumors; and DZD2269, which is in Phase I clinical ... [Read more]

Sector Healthcare
Founded 2017
Employees 581
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688192
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.